Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

40
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
40
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

31
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
31
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

27
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
27
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

39
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
39
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

30
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
30

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Multiscale Dissolution Simulation of Particles from a Tablet in Dissolution Apparatus by Coupling Discrete Element with Lattice Boltzmann Methods.

Pharmaceutical research·2026
Same author

Evaluation of a Novel Flexible Cage System for C5-C6 Fixation: A Finite Element Study Against Conventional ACDF Implants.

Bioengineering (Basel, Switzerland)·2026
Same author

Editorial: Integrated diagnostics and biomarker discovery in endocrinology and biomedical sciences, volume II.

Frontiers in endocrinology·2025
Same author

Recent advances in polymer-based drug delivery systems for atopic dermatitis: enhancing therapeutic efficacy and outcomes.

Materials today. Bio·2025
Same author

Challenges and innovations in long-acting injectable formulations: can formulation design space be rationalized?

The Journal of pharmacy and pharmacology·2025
Same author

Long-Acting injectable buprenorphine PLGA microparticle formulation.

International journal of pharmaceutics·2025

関連する実験動画

Updated: Feb 19, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K

長期にわたるブプレノルフィンの投与のためのコンパクト化された固体インプラント製剤.

Andrew Otte1, Kinam Park1

  • 1Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.

Journal of controlled release : official journal of the Controlled Release Society
|February 17, 2026
PubMed
まとめ

新しい生物分解性インプラントは,3ヶ月以上持続的なブプレノルフィンの放出を提供し,潜在的に治療の遵守とオピオイド使用障害 (OUD) のアウトカムを改善します. 長期作用薬のこの進歩は,OUD管理における重要なニーズに対応しています.

キーワード:
ブプレノルフィンはブプレノルフィンのコンパクト・ロッド・フォーミュレーション長期にわたって作用する注射薬オピオイド使用障害 オピオイド使用障害PLGAのロッドが使われています.

さらに関連する動画

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

898
Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation
08:56

Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation

Published on: August 1, 2010

17.9K

関連する実験動画

Last Updated: Feb 19, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

898
Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation
08:56

Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation

Published on: August 1, 2010

17.9K

科学分野:

  • 薬理学 薬理学とは
  • 材料科学 材料科学とは
  • 薬物の配送システムです.

背景:

  • オピオイド使用障害 (OUD) は,米国における重要な公衆衛生問題である.
  • ブプレノルフィンによる薬剤補助治療は,重要な管理戦略です.
  • 既存の長効ブプレノルフィン製品は,1週間または1ヶ月間の放出を提供します.

研究 の 目的:

  • 持続的なブプレノルフィンの放出のための新しい生物分解性ポリ・ラクチド・コ・グリコリド (PLGA) 棒製剤を開発する.
  • 薬物の放出を3ヶ月またはそれ以上の期間で達成するために.
  • PLGAシステムに共通する初期バーストリリースを最小限にするために.

主な方法:

  • ブプレノルフィンフリーベースとPLGAは,プラストメーターを使用して熱的に固体棒に圧縮されました.
  • 製造には165-180°Cの温度と4~16kgの圧縮負荷が必要でした.
  • ネズミと犬のモデルでインビオの薬理学研究が行われました.

主要な成果:

  • 開発されたPLGA棒インプラントは,体重70%のブプレノルフィンを含んでいます.
  • 最適化された圧縮を通じて初期爆破の放出を最小限に抑え,毛穴形成を減らす.
  • 動物モデルで3ヶ月を超える持続的なブプレノルフィンの血濃度が実証されています.

結論:

  • 新しい生物分解性PLGA棒は,3ヶ月以上持続的なブプレノルフィンの放出を提供します.
  • これらの長時間作用するインプラントは,OUD治療の有望な進歩を表しています.
  • OUD管理における患者のアデバーンスを強化し,臨床結果を改善する可能性がある.